vs
Side-by-side financial comparison of ABEONA THERAPEUTICS INC. (ABEO) and Alpha Cognition Inc. (ACOG). Click either name above to swap in a different company.
Alpha Cognition Inc. produced more free cash flow last quarter ($-7.1M vs $-23.7M).
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of novel gene and cell therapies for life-threatening rare genetic diseases. Its pipeline addresses unmet medical needs, serving patient populations across North America and European markets with limited treatment alternatives.
ABEO vs ACOG — Head-to-Head
Income Statement — Q3 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $2.8M |
| Net Profit | $-5.2M | $-6.9M |
| Gross Margin | — | — |
| Operating Margin | — | -283.7% |
| Net Margin | — | -245.5% |
| Revenue YoY | — | — |
| Net Profit YoY | 82.9% | — |
| EPS (diluted) | $-0.10 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.8M | ||
| Q3 25 | $0 | $2.8M | ||
| Q2 25 | $400.0K | $1.7M | ||
| Q1 25 | — | $2.9M |
| Q4 25 | — | $-6.9M | ||
| Q3 25 | $-5.2M | $-1.3M | ||
| Q2 25 | $108.8M | $-10.5M | ||
| Q1 25 | — | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 96.7% | ||
| Q1 25 | — | 99.6% |
| Q4 25 | — | -283.7% | ||
| Q3 25 | — | -187.0% | ||
| Q2 25 | -5698.0% | -346.1% | ||
| Q1 25 | — | -125.9% |
| Q4 25 | — | -245.5% | ||
| Q3 25 | — | -46.4% | ||
| Q2 25 | 27208.3% | -632.7% | ||
| Q1 25 | — | -68.5% |
| Q4 25 | — | $-0.10 | ||
| Q3 25 | $-0.10 | $-0.30 | ||
| Q2 25 | $1.71 | $-0.65 | ||
| Q1 25 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $66.0M |
| Total DebtLower is stronger | $19.8M | — |
| Stockholders' EquityBook value | $171.2M | $62.5M |
| Total Assets | $231.1M | $79.7M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $66.0M | ||
| Q3 25 | $207.1M | $35.4M | ||
| Q2 25 | $225.5M | $39.4M | ||
| Q1 25 | — | $45.5M |
| Q4 25 | — | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q1 25 | — | — |
| Q4 25 | — | $62.5M | ||
| Q3 25 | $171.2M | $33.9M | ||
| Q2 25 | $163.6M | $31.9M | ||
| Q1 25 | — | $40.8M |
| Q4 25 | — | $79.7M | ||
| Q3 25 | $231.1M | $46.3M | ||
| Q2 25 | $246.2M | $45.1M | ||
| Q1 25 | — | $48.6M |
| Q4 25 | — | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-21.2M | $-6.9M |
| Free Cash FlowOCF − Capex | $-23.7M | $-7.1M |
| FCF MarginFCF / Revenue | — | -252.6% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.9M | ||
| Q3 25 | $-21.2M | $-5.3M | ||
| Q2 25 | $-18.8M | $-6.1M | ||
| Q1 25 | — | $-2.0M |
| Q4 25 | — | $-7.1M | ||
| Q3 25 | $-23.7M | $-5.4M | ||
| Q2 25 | $-21.7M | $-6.1M | ||
| Q1 25 | — | $-2.1M |
| Q4 25 | — | -252.6% | ||
| Q3 25 | — | -188.8% | ||
| Q2 25 | -5421.3% | -370.9% | ||
| Q1 25 | — | -72.0% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 725.3% | 0.5% | ||
| Q1 25 | — | 2.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.17× | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
